- Home
- CFBK vs NTHI Comparison
CFBK vs NTHI Comparison
Compare CFBK & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFBK | NTHI |
|---|---|---|
| Founded | 1892 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.4M | 195.5M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | CFBK | NTHI |
|---|---|---|
| Price | $23.78 | $10.19 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $29.00 | N/A |
| AVG Volume (30 Days) | 32.7K | ★ 68.0K |
| Earning Date | 11-03-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 21.79 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $50,724,000.00 | $59,990.00 |
| Revenue This Year | $39.98 | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $9.57 | ★ N/A |
| Revenue Growth | ★ 14.25 | N/A |
| 52 Week Low | $19.23 | $3.20 |
| 52 Week High | $28.75 | $25.00 |
Technical Indicators
Market Signals| Indicator | CFBK | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 58.54 |
| Support Level | $23.69 | $8.63 |
| Resistance Level | $23.98 | $9.75 |
| Average True Range (ATR) | 0.18 | 0.88 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 21.50 | 95.59 |
Price Performance
Historical ComparisonAbout CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).